➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
Boehringer Ingelheim
AstraZeneca
Moodys

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Patent: 10,144,779

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,779
Title:Anti-CTLA-4 antibodies and methods of use thereof
Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Inventor(s): van Dijk; Marc (Bosch en Duin, NL), Mundt; Cornelia Anne (Lorrach, DE), Ritter; Gerd (New York, NY), Schaer; David (Mamaroneck, NY), Wolchok; Jedd David (New York, NY), Merghoub; Taha (Jersey City, NJ), Savitsky; David Adam (Boxford, MA), Wilson; Nicholas Stuart (San Carlos, CA)
Assignee: AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY)
Application Number:15/166,305
Patent Claims:see list of patent claims

Details for Patent 10,144,779

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Mallinckrodt
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.